Scancell
Oxford, United Kingdom

Scancell is a clinical-stage immuno-oncology specialist that is developing two innovative and flexible therapeutic vaccine platforms. ImmunoBody and Moditope induce high avidity cytotoxic CD8 and CD4 responses, respectively, with the potential to treat various cancers.

www.scancell.co.uk

Investment Perspective

Scancell has reported H119 results in line with expectations. The cash position was £7.6m, with the net loss of £3.24m compensated for by the two equity raises, totalling £14.9m, over the past year. Development appears to be progressing well, with important clinical programmes expected to start patient recruitment during the next two quarters. Additionally, in January 2019 the management team has been strengthened by two important new hires. As detailed in our Initiation note, we value the company, using a risk-adjusted DCF model, at £82.0m, or 21.1p a share.

Market information

SymbolPrimary exchangeCurrency
SCLPAIM LondonGBP
Last PriceMarket Cap
52 Week Low52 Week High

Research

Interim results show progress being maintained
Update | 31 Jan 2019
Missing out on the CRUK Grand Challenge
Lighthouse | 23 Jan 2019
Opening new pathways in immuno-oncology
Initiation | 28 Nov 2018

Recent News

Grant of Japanese patent that protects Moditope immunotherapy platform
08 Apr 2019
CSO receives Waldenstrom award from Swedish Society of Oncology
21 Mar 2019
IP portfolio strengthened
20 Mar 2019
Interim H119 results
31 Jan 2019